# LiDer (NCT06385548)

> Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06385548
- Phase: PHASE1, PHASE2
- Status: WITHDRAWN
- Sponsor: Vall d'Hebron Institute of Oncology
- Conditions: Endometrial Cancer
- Interventions: Lurbinectedin; Dostarlimab
- Enrollment: 0
- Primary outcome: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) Determination
- Primary outcome: Evaluation of Lurbinectedin and Dostarlimab Combination Therapy in Advanced/Recurrent Cervical Cancer Patients

## Commentary we found

- YouTube: 2
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lider-nct06385548